Exome sequencing reveals a potential mutational trajectory and treatments for a specific pancreatic cancer patient

: Pancreatic cancer is the fourth biggest killer, and has one of the worst prognoses, of any cancer type. Approximately 95% of patients diagnosed with pancreatic cancer will not survive beyond 5 years post diagnosis, and these statistics have barely improved in over 40 years. Here, genomic changes in one particular patient with stage IV metastatic pancreatic cancer were explored to suggest a potential personalized treatment. In particular, exome sequencing of genomic DNA extracted from blood and the cancer biopsy was utilized with the aim of identify-ing mutational drivers of the cancer. This analysis revealed a splice site mutation in RBCK1 as the most promising driver of the cancer and a therapy based on a pan-cyclin-dependent kinase (pan-CDK) inhibitor, flavopiridol. This study suggests that drugs whose effectiveness is unclear for general populations of cancer sufferers should possibly be reconsidered for specific patients where the drug could be rationally argued to improve outcome.

[1]  S. Das,et al.  Inherited pancreatic cancer syndromes. , 2012, Cancer journal.

[2]  Lincoln D. Stein,et al.  Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes , 2012, Nature.

[3]  A. Scarpa,et al.  Molecular Pathology of Pancreatic Cancer: From Bench-to-Bedside Translation , 2012, Current drug targets.

[4]  Ken Chen,et al.  SomaticSniper: identification of somatic point mutations in whole genome sequencing data , 2012, Bioinform..

[5]  A. Gonzalez-Perez,et al.  Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. , 2011, American journal of human genetics.

[6]  Andrew Menzies,et al.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.

[7]  Alan Ashworth,et al.  Synthetic lethal approaches to breast cancer therapy , 2010, Nature Reviews Clinical Oncology.

[8]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[9]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[10]  A. Giordano,et al.  CDK inhibitors: from the bench to clinical trials. , 2010, Current drug targets.

[11]  K. Dahlman-Wright,et al.  RBCK1 drives breast cancer cell proliferation by promoting transcription of estrogen receptor alpha and cyclin B1. , 2010, Cancer research.

[12]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[13]  G. Doyle,et al.  Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer , 2009, Journal of oncology.

[14]  M. Gonen,et al.  Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors , 2009, Clinical Cancer Research.

[15]  W. Scheithauer,et al.  Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Gary K. Schwartz,et al.  A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer , 2009, Pancreatology.

[17]  Alan Ashworth,et al.  Drug resistance caused by reversion mutation. , 2008, Cancer research.

[18]  C. Hudis,et al.  Phase I Dose-Finding Study of Weekly Docetaxel Followed by Flavopiridol for Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.

[19]  W. Scheithauer,et al.  Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Ashworth,et al.  The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability , 2006, Oncogene.

[21]  A. Seth,et al.  Novel RING E3 ubiquitin ligases in breast cancer. , 2006, Neoplasia.

[22]  A. Joe,et al.  Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy , 2006, Nature Clinical Practice Oncology.

[23]  W. Kaelin.  The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.

[24]  Minoru Yoshida,et al.  Nuclear-Cytoplasmic Shuttling of a RING-IBR Protein RBCK1 and Its Functional Interaction with Nuclear Body Proteins* , 2005, Journal of Biological Chemistry.

[25]  M. Stratton,et al.  The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website , 2004, British Journal of Cancer.

[26]  Steven Henikoff,et al.  SIFT: predicting amino acid changes that affect protein function , 2003, Nucleic Acids Res..

[27]  G. Christofori,et al.  Cadherins and the tumour progression: is it all in a switch? , 2002, Cancer letters.

[28]  O. Ohara,et al.  Mammalian fat3: a large protein that contains multiple cadherin and EGF-like motifs. , 2002, Biochemical and biophysical research communications.

[29]  J. Haber.  DNA recombination: the replication connection. , 1999, Trends in biochemical sciences.

[30]  S. Kaufmann,et al.  Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. , 1996, Cancer research.

[31]  E. Sausville,et al.  Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. , 1996, Cancer research.

[32]  David O. Morgan,et al.  Principles of CDK regulation , 1995, Nature.

[33]  E. Sausville,et al.  Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. , 1992, Journal of the National Cancer Institute.

[34]  Peter J. Bryant,et al.  The fat tumor suppressor gene in Drosophila encodes a novel member of the cadherin gene superfamily , 1991, Cell.

[35]  D. Shibata,et al.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes , 1988, Cell.

[36]  T. Dobzhansky,et al.  Genetics of Natural Populations. Xiii. Recombination and Variability in Populations of Drosophila Pseudoobscura. , 1946, Genetics.

[37]  M. Berretta,et al.  Molecular diagnosis of pancreatic cancer: where do we stand? , 2010, Frontiers in bioscience.

[38]  T. Takada,et al.  Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. , 2008, Archives of surgery.

[39]  H. Dietz,et al.  Nonsense-mediated mRNA decay in health and disease. , 1999, Human molecular genetics.

[40]  U. Kikkawa,et al.  Molecular cloning and characterization of RBCK2, a splicing variant of a RBCC family protein, RBCK1. , 1998, FEBS letters.

[41]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[42]  F. Figge,et al.  Cancer research, past, present, and future. , 1953, Bulletin of the School of Medicine.